目前基金处于筹划设立阶段，合伙协议尚未正式签署，上述投资份额以最终签署的正式合伙协议为准。 公司董事会提请股东会授权公司管理层及相关人士全权办理本次对外投资所涉及的具体事项，根据基金 管理人发送的《缴付出资通知》参与基金投资，并依照相关法律法规的规定及时推进基金设立、备案及 待基金依法设立并完成备案后，由基金平价受让深圳成大生物及成大医疗持有基因启明的全部股权等相 关事宜。 基金总规模不超过100,000万元，设立时的规模为50,200万元。基金由辽宁成大和成大生物发起设立，其 中：成大沿海作为基金管理人、普通合伙人及执行事务合伙人，拟认缴出资人民币100万元，约占基金 设立时份额的0.1992%；深圳成大生物作为普通合伙人及执行事务合伙人，拟认缴出资人民币100万 元，约占基金设立时份额的0.1992%；辽宁成大作为有限合伙人，拟以自有资金认缴出资人民币10,000 万元，约占基金设立时份额的19.9203%；成大生物作为有限合伙人，拟以自有资金认缴出资人民币 40,000万元，约占基金设立时份额的79.6813%。 该基金投资期内各投资人将根据基金投资要求进行实缴，后续出资将由普通合伙人在基金合伙协议签署 ...

深圳市倚锋投资管理企业(有限合伙)是国内最早一批生物医药专业投资机构，专注于全球生物医药投 资。本次投资有助于公司借助专业投资机构的优质资源，帮助公司业务和客户导入及战略资源引入。倚 锋云鼎基金专项投资于倚锋润君基金，倚锋润君基金主要投资于医疗健康板块的原创新药、高端医疗器 械、生物科技及国内外相关领域的优质标的企业，所投资项目可能与公司存在业务合作等协同关系。 智通财经APP讯，博腾股份(300363.SZ)发布公告，公司拟以1元对价受让陈彦希持有的深圳市倚锋云鼎 创业投资合伙企业(有限合伙)(简称"倚锋云鼎基金")部分份额，受让完成后，公司将按照《合伙协议》 的约定履行2000万元认缴份额的实缴出资义务。倚锋云鼎基金专项投资于杭州倚锋润君创业投资合伙企 业(有限合伙)(简称"倚锋润君基金")，公司将通过投资倚锋云鼎基金，实现对倚锋润君基金的间接投 资。 ...

智通财经APP讯，博腾股份(300363.SZ)发布公告，公司拟以1元对价受让陈彦希持有的深圳市倚锋云鼎 创业投资合伙企业(有限合伙)(简称"倚锋云鼎基金")部分份额，受让完成后，公司将按照《合伙协议》 的约定履行2000万元认缴份额的实缴出资义务。倚锋云鼎基金专项投资于杭州倚锋润君创业投资合伙企 业(有限合伙)(简称"倚锋润君基金")，公司将通过投资倚锋云鼎基金，实现对倚锋润君基金的间接投 资。 深圳市倚锋投资管理企业(有限合伙)是国内最早一批生物医药专业投资机构，专注于全球生物医药投 资。本次投资有助于公司借助专业投资机构的优质资源，帮助公司业务和客户导入及战略资源引入。倚 锋云鼎基金专项投资于倚锋润君基金，倚锋润君基金主要投资于医疗健康板块的原创新药、高端医疗器 械、生物科技及国内外相关领域的优质标的企业，所投资项目可能与公司存在业务合作等协同关系。 ...

Core Viewpoint - The company has announced the establishment of an industrial fund to enhance strategic development and capitalize on investment opportunities in the biopharmaceutical sector [1] Group 1: Investment Details - The company will collaborate with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. to set up the Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership (Limited Partnership) [1] - The total investment amount for the industrial fund is RMB 50.01 million, with the company contributing RMB 25 million, accounting for 49.99% of the total subscription [1] - The fund will primarily invest in early and mid-stage biopharmaceutical projects [1] Group 2: Regulatory Compliance - The investment partnership has completed the filing procedures with the Asset Management Association of China and has obtained the Private Investment Fund Filing Certificate [1]

Core Viewpoint - The article highlights the ongoing efforts of Shanghai Guotou Company in promoting the biopharmaceutical industry through the establishment of various funds aimed at supporting innovation and capital infusion in the sector [1][2]. Group 1: Fund Establishment and Goals - The Shanghai Guotou Company has signed agreements with 10 institutions to further develop its biopharmaceutical industry fund matrix, marking a significant step in its capital management strategy [1]. - A total of 22.5 billion yuan has been committed to the Shanghai Biopharmaceutical M&A Fund, with the aim of enhancing the industry through strategic investments and mergers [2]. - The Shanghai Biopharmaceutical Industry Mother Fund, with a total scale of 22.5 billion yuan, aims to support the entire innovation chain of the biopharmaceutical industry [1][2]. Group 2: Industry Growth and Performance - Since 2021, the Shanghai biopharmaceutical industry has seen a compound annual growth rate of 8.94%, with the industry scale increasing from 761.71 billion yuan in 2021 to 984.70 billion yuan in 2024 [3]. - The industry scale reached 500.57 billion yuan in the first half of 2025, with projections indicating it will surpass one trillion yuan by the end of the year [3]. Group 3: Event Structure and Activities - The 2025 Shanghai International Biopharmaceutical Week features a structured layout of activities, including one opening event, one exhibition, and 15 thematic forums focused on various aspects of the biopharmaceutical industry [2]. - The event aims to create a year-round platform for ongoing activities related to innovation, policy, and capital in the biopharmaceutical sector [2].

Core Viewpoint - The company Zhaoyan New Drug announced its intention to establish a seed fund in partnership with Yifeng Capital and Yifeng Mingyuan, focusing on investments in the biomedicine and high-end medical device sectors, with a total fundraising target of 12.75 million RMB [2][3]. Group 1: Company Overview - Zhaoyan New Drug, founded in 1995, is a specialized contract research organization (CRO) headquartered in Beijing, with over 2,500 professionals across multiple locations including Beijing, Suzhou, and the United States [3][4]. - The company is listed on both A-share and Hong Kong stock markets, categorized as an "A+H" enterprise [4]. Group 2: Investment Details - The seed fund will have a total fundraising scale of 12.75 million RMB, with Zhaoyan New Drug or its designated subsidiary committing up to 10 million RMB as a limited partner (LP) [2]. - The fund aims to support strategic emerging industries and key sectors prioritized by the Shenzhen government, particularly in biomedicine and high-end medical devices [3]. Group 3: Partner Information - Yifeng Capital, established in 2012, focuses on investments in the biomedicine sector and is recognized as one of the top venture capital institutions in Shenzhen [2][3]. - The investment portfolio of Yifeng Capital includes several successful companies that have gone public, such as Microchip Biotech and Apexigen [3].

Core Viewpoint - Jiet Bio plans to establish an industrial fund to invest in early and mid-stage biopharmaceutical projects, with a total fund size of 50.01 million yuan [1] Investment Details - The fund will be initiated in partnership with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. [1] - Jiet Bio intends to contribute 25 million yuan, representing a 49.99% stake in the fund [1] - The partnership will have a duration of 7 years, with the first 4 years designated for investment and the last 3 years for exit [1] Transaction Nature - The investment does not constitute a related party transaction or a major asset restructuring [1]